3 Cbd Oil Stocks That Will Make You Rethink Your Portfolio

Profit Confidential pulled together a number of recent reports showing that the CBD oil stock market is set to break out in the next few years, carving out its own niche among marijuana stocks. Forbes, forecasted an increase of 700 percent by 2020, while Hemp Business Journal sees CBD oil reaching $2.1 billion by that same year. It is a mature market, far removed from the weed smoking, pot smoking stoner days of yore.

Even as cannabis stocks continue to experience volatility, CBD oil sees record profits. The sector is primed for an influx of investors. With that in mind, here are three CBD oil stocks that will make you rethink your portfolio:

[embedded content]

Isodiol International Inc.

Global Bioactive CBD oil company Isodiol International Inc. (CSE:ISOL) (ISOLF) announced recently the acquisition of several global assets, placing them on a level playing field with any of the top marijuana stocks in the industry. Along with their recent deals, the company has begun to develop a new facility in China where they plan to take certified organic hemp and extract cannabinoids and terpenes.

Isodiol’s new strategic assets in the U.K., Brazil, and China look like they will give the company true global dominance in the growing CBD oil sector; a pot stock so steeped in extracts that CBD oil stock seems the more appropriate term. “These transactions mark major milestones for Isodiol. The acquisitions ensure the company has a continued source of CBD and scalability of production as our international expansion continues to generate additional market demand for our products,” remarked CEO Marcos Agramont.

Isodiol currently trades at $0.84 on the OTC markets, with a market cap of $240 million. With the growth in the CBD oil market set on an upwards trajectory, now may be the time for investors to consider this globally dominant cannabis stock —cbd oil stock option.

[embedded content]

Neptune Wellness Solutions

Wellness products company Neptune Wellness Solutions (NASDAQ:NEPT) (TSX:NEPT) announced earlier this year a partnership with Tetra Bio-Pharma Inc. to develop, commercialize, and market cannabinoid oil products for pain and inflammation. The former krill oil supply company made a move towards the CBD market last year and has not looked back, making the newest player in the CBD oil stock market the most intriguing.

In a presentation explaining the move to the CBD oil business, Neptune called it a natural fit, with the company sliding from one wellness product to another. As CEO Jim Hamilton said in an interview with The Cannabist, “[Customers are] looking for inflammation [treatments], they’re looking for sleep aids, they’re looking for anxiety relief. Think of all the people taking sleeping pills and all the people taking opioids. I think there’s a whole community that is going to want to embrace elements of this business.”

Neptune currently trades at $2.90 on the Nasdaq with a market cap of $225 million. A new entrant into the marijuana stock market, their foray into CBD oil makes them an intriguing look for investors.

[embedded content]

Medical Marijuana Inc.

The aptly named Medical Marijuana Inc. (OTC:MJNA) announced recently that March 2018 was the company’s best month ever for revenues. With their popular subsidiary Kannaway under their belt and a popular online CBD oil store, the first-ever publicly-traded marijuana stock is in many ways the standard in the CBD oil game.

"March, 2018 was the largest revenue month in the history of our Company.  We look forward to sharing our full 2017 results in our Annual Report which will be filed this month," said Medical Marijuana, Inc. CEO Dr. Stuart Titus in a statement. Kannaway once again looks to make waves with their Empower National Convention in Las Vegas this April.

Medical Marijuana Inc. currently trades at $0.12 per share with a market cap near $360 million. This is one CBD oil stock on solid ground for any marijuana stock investor.